Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.

The present invention generally relates to systems and methods for monitoring and/or providing feedback for drugs or other pharmaceuticals taken by a subject. In one aspect, the present invention is directed to devices and methods for determining a species within the skin of a subject; and producing feedback to a subject based on the determination of the species. The feedback may be, for example, visual, audible, tactile, a change in temperature, etc. In some cases, information regarding the determination of the species may be transmitted to another entity, e.g., a health care provider, a computer, a relative, etc., which may then provide feedback to the subject in some fashion. In some cases, the feedback may be directly indicative of the species, e.g., whether the species is present, the concentration of the species, whether a by-product of a reaction involving the species is present, whether a compound affected by the species is present, etc. However, the feedback may also be indirect in some embodiments. For example, the subject may be presented with an external reward, e.g., based on the determination of the species within the skin. For instance, a reward such as cash, coupons, songs, discounts, personal items, etc., may be offered based on the level of compliance of the subject. Still other aspects of the invention are generally directed to kits involving such devices (with or without the drug to be monitored), methods of promoting such systems, or the like.

A system for determining the presence of cell-free non-coding RNA (cfNCR) biomarkers in interstitial fluid includes a microfluidic device for non-invasively and passively accessing interstitial fluid from a patient. The microfluidic device is formed of a substrate containing multiple vertical micro channels therethrough, wherein at a first end of each of the multiple vertical micro channels a microheater is formed for controllably ablating a portion of dry dead skin cells to access the interstitial fluid; and wherein at a second end of each of the multiple vertical micro channels is a horizontal micro channel for receiving accessed interstitial fluid from a vertical micro channel and guiding the accessed interstitial fluid to a common collection port.

A system for analyzing a patient using a transcutaneous sensor, having a base unit for attaching to the patient, an injector, releasably connectable to the base unit, for the transcutaneous insertion of the sensor into the patient, and a detection unit, releasably connectable to the base unit, for generating measurement data by the sensor. The base unit has a holding device which is configured to cooperate with the injector and detection unit such that, in a detection configuration with the detection unit arranged on the base unit, a contact pressure is applied to the sensor by the holding device for frictional fixing, and in an injection configuration with the injector arranged on the base unit, a lower contact pressure than in the detection configuration is applied to the sensor by the holding device.

Method and apparatus for providing an integrated analyte sensor and data processing unit assembly is provided.

A fluid extraction or filtration device for removing fluid from a body, the device comprising an array of microneedles for contacting fluid in said body and an absorbent gel matrix in fluid communication with said array of microneedles. There is further provided a combined fluid extraction and sampling device and methods employing the device(s), for example in determining the level of a target species in a sample of fluid, transdermal dialysis and renal replacement therapy. There is further provided an absorbent gel matrix for use in the treatment of uraemia and a haemodialysis filter comprising an absorbent gel matrix. Use of such a matrix is described in the context of methods including haemodialysis, transdermal dialysis and gastrointestinal dialysis.

A measuring chamber device for an optically operating sensor for determining a concentration of a substance that is contained in tissue fluid of a mammal. The measuring chamber device has a measuring chamber filled with a liquid measuring medium and a wall with better diffusion permeability for the substance than for other constituents of the tissue fluid. A transmitter device for emitting optical radiation into the measuring chamber, and a receiver device for receiving optical radiation that has passed through the measuring chamber are also provided.

In certain embodiments, a method for communicating with a fetus may include providing, on an electronic device, a user interface configured to facilitate wireless communication of signals between the electronic device and at least one implanted device located in proximity to the fetus; and responsive to a user selecting a communication selection element, causing the wireless communication of signals inclusive of content data between the electronic device and implanted device.

A system for delivering treatment to a biological subject, the system including: at least one substrate including a plurality of microstructures configured to breach a stratum corneum of the subject; at least one sensor operatively connected to at least one microstructure, the at least one sensor being configured to measure response signals from the at least one microstructure; at least one treatment delivery mechanism operatively coupled to at least one microstructure to deliver treatment via at least one microstructure; and, one or more electronic processing devices that are configured to control the at least one treatment delivery mechanism to thereby deliver treatment to the subject at least partially in accordance with the measured response signals.

A transdermal patch comprising: a microneedle in a protruding position, protruding from the transdermal patch; and immobilised functional molecules; wherein a fluid path is provided between the distal tip of the microneedle and the immobilised functional molecules; and the functional molecules are selected to interact with selected target molecules so as to convert or trap said target molecules. The device intends to dynamically curb the postprandial insulin spike offering an unprecedented therapeutic effect for diabetes and obesity with significant benefits in morbidity and without strict diet. The device offers unprecedented phenylketonuria management that removes the burden of strict diet. The device offers easy removal of autoantibodies, low density lipoprotein and other pathogenic molecules. The device can be used in any disorder that requires enzymatic replacement or elimination of pathogenic molecules via biochemical conversion or trapping.